Results of appeal of delisting determination

6 july 2023 biodexa pharmaceuticals plc (“biodexa” or the “company”) results of appeal of delisting determination biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announced today that, on july 5, 2023, the nasdaq stock market llc's (“nasdaq”)hearings panel notified the company that, in connection with its request for a temporary exception to regain compliance with nasdaq's requirement that the closing bid price of its securities remain at $1.00 or higher as required by nasdaq listing rule 5810(c)(3)(a) (the “minimum bid price rule”), and further to the company's recently completed consolidation of its american depositary receipts, which had the effect of a one-for-80 reverse split, it has been granted an exception until july 18, 2023 to demonstrate compliance with the minimum bid price rule. if the company's securities fail to regain compliance with the minimum bid price rule by that date, nasdaq will delist the securities.
BDRX Ratings Summary
BDRX Quant Ranking